FDAsafety guidance66% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · Antibiotic
- Sub-indication
- General
Related signal: FDA Approves Supplemental Applications for ZYVOX by Pfizer